Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates - Episode 13
Targeting of HER3: Insights from HERTHENA-Lung01
Helena A. Yu, MD, initiates a discussion on the role of HER3 in the development of resistance to EGFR-targeted therapies. She also examines the HERTHENA-Lung01 study and analyzes the emerging data from this trial.
- Please discuss the role of HER3 in the development of resistance to EGFR targeted therapies. (Manickavasagar, et al. Lung Cancer Mang, 2021; Engelman, et al. Science, 2007)
- Describe the rationale for targeting HER3 in patients with EGFR TKI resistance.
- What have data shown with treatment strategies using dual targeting of HER3 and EGFR?
- Please review the rationale and study design for HERTHENA-Lung01 and discuss emerging study data and its implications on the treatment landscape. (Goto, et al. WCLC 2023. Abstract OA05.03; Johnson, et al. ESMO 2023. Abstract 1319MO)
- Briefly outline the study design and key endpoints. What are your perceptions around the brain mets data presented at ESMO this past year?
- What are some key takeaways from safety data?
- What implications may these findings have on clinical practice?